Brandon Wei

ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Founded in 1958, Merrill Lynch Piece Fenner & Smith, Inc. is an SEC registered broker/dealer located in New York City. The firm is a subsidiary of BAC North America Holding Co. and their ultimate parent is Bank of America Corp. (NYSE BAC).

Exploit Technologies Pte Ltd. operates as intellectual property portfolio company. It is a technology company which transfer arm of the Agency for Science, Technology and Research. Exploit Technologies and is headquartered in Singapore.

Part of Aslan Pharmaceuticals Ltd., Aslan Pharmaceuticals Taiwan Ltd. develops novel medicines. The company is based in Taipei, Taiwan and was founded in 2014.

Part of Aslan Pharmaceuticals Ltd., Aslan Pharmaceuticals Hong Kong Ltd. is a pharmaceutical manufacturing company. The company is based in Hong Kong, Hong Kong.

Hummingbird Bioscience Pte Ltd. operates as a biotechnology company. It engages in the research and development of novel cancer immuno-therapeutics. The firm develops antibodies against a number of oncology and immuno-oncology targets. The company was founded by Jerome Boyd-Kirkup, Piers Ingram, and Lan Zhang in 2015 and is headquartered in Singapore.

Dotbio Pte Ltd. was founded in 2017 and is based in Singapore, Singapore. The Singaporean company takes an innovative therapeutic approach towards the ideal treatment by rapidly prototyping multi-functional antibodies to identify molecules with synergistic activity combinations, optimal architectures, and unique mechanisms of action. Dotbio's approach involves the use of its modular dotbody technology platform, its cofi and hot-cofi stabilization technologies, high-throughput miniaturized assays, and data analytics to generate unique therapeutic molecules that target both extracellular and intracellular disease drivers. Dotbio has a pipeline of such molecules.